- Home
- ONTO vs ABVX Comparison
ONTO vs ABVX Comparison
Compare ONTO & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ONTO | ABVX |
|---|---|---|
| Founded | 1940 | 2013 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9B | 9.2B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ONTO | ABVX |
|---|---|---|
| Price | $214.67 | $124.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 11 |
| Target Price | ★ $183.75 | $130.09 |
| AVG Volume (30 Days) | 907.8K | ★ 984.0K |
| Earning Date | 02-19-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.55 | N/A |
| Revenue | ★ $1,002,336,000.00 | $6,231,374.00 |
| Revenue This Year | $3.82 | $6.80 |
| Revenue Next Year | $18.15 | N/A |
| P/E Ratio | $62.64 | ★ N/A |
| Revenue Growth | ★ 6.38 | N/A |
| 52 Week Low | $85.88 | $4.77 |
| 52 Week High | $229.87 | $148.83 |
Technical Indicators
Market Signals| Indicator | ONTO | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 59.44 | 57.35 |
| Support Level | $180.18 | $115.93 |
| Resistance Level | $229.87 | $116.72 |
| Average True Range (ATR) | 11.51 | 5.06 |
| MACD | -0.44 | 1.14 |
| Stochastic Oscillator | 67.66 | 94.60 |
Price Performance
Historical ComparisonAbout ONTO Onto Innovation Inc.
Onto Innovation Inc is engaged in the design, development, manufacture, and support of high-performance control metrology, defect inspection, lithography, and data analysis systems used by microelectronics device manufacturers. The Company and its subsidiaries currently operate in a single operating segment. The company mainly operates in the United States, Southeast Asia, China, Japan, and Europe, with Taiwan and South Korea the sources of total revenue.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.